WOK WORK Medical Technology Group LTD Annual reports only
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1929783 · Fiscal year ends 09/30
Financial factors as of 2025-09-30 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-14.4%
TTM net income YoY69.3%
TTM EPS YoY85.2%
Revenue 3-yr CAGR-20.6%
Net income 3-yr CAGR—
Margins
Gross margin23.8%
Operating margin—
Net margin-10.9%
FCF margin49.9%
EBITDA margin—
Returns
ROE-6.8%
ROA-3.1%
ROIC (approx.)—
Asset turnover0.28x
Leverage & solvency
Liabilities / assets36.2%
Debt / equity0.00x
Current ratio1.71x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-5.82x
Accruals ratio-21.1%
Payout ratio—
Capex / revenue13.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-09-30 | FY20242024-09-30 |
|---|---|---|
| Income statement | ||
| Revenue | $9.85M | $11.51M |
| Gross profit | $2.34M | $2.87M |
| R&D expense | $435,311 | $302,511 |
| SG&A expense | $2.33M | $4.56M |
| Interest expense | $503,519 | $557,571 |
| Pretax income | -$1.08M | -$3.67M |
| Income tax | $119,053 | -$125,291 |
| Net income | -$1.07M | -$3.49M |
| EPS (basic) | -0.04 | -0.27 |
| EPS (diluted) | -0.04 | -0.27 |
| Weighted avg. shares (diluted) | 28.98M | 12.71M |
| Balance sheet | ||
| Cash & equivalents | $4.09M | $6.56M |
| Receivables | $615,838 | $1.65M |
| Inventory | $2.46M | $3.18M |
| Current assets | $20.46M | $20.83M |
| PP&E, net | $10.59M | $11.37M |
| Intangibles | $959,116 | $1.04M |
| Total assets | $33.16M | $36.25M |
| Current liabilities | $11.97M | $20.18M |
| Short-term debt | $6.39M | $13.32M |
| Total liabilities | $11.99M | $20.18M |
| Shareholders' equity | $18.34M | $13.19M |
| Shares outstanding | — | 14.59M |
| Cash flow statement | ||
| Operating cash flow | $6.24M | -$2.23M |
| Capital expenditure | $1.33M | $9.23M |
| Free cash flow | $4.91M | -$11.45M |
| Investing cash flow | -$7.61M | -$9.06M |
| Financing cash flow | -$898,212 | $15.66M |
| Depreciation & amortization | $923,108 | $1.41M |
Free plan shows the latest 2 periods; Pro shows all 4 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.